Critically ill COVID-19 associated trait genetics reveals CDK6 inhibitors as potential treatment

Joern E. Klinger[1], Charles N. J. Ravarani[1], Colin Bannard[2], Margaretha R. J. Lamparter[1], Alexander R. E. C. Schwinges[1], Justin L. Cope[1], Hannes A. Baukmann[1], Marco F. Schmidt[1*]

[1]biotx.ai GmbH, Am Mühlenberg 11, 14476 Potsdam, Germany.

[2]Institute of Population Health, University of Liverpool, Eleanor Rathbone Building, Bedford Street South, Liverpool L69 7ZA, United Kingdom.

*e-Mail: ms@biotx.ai

Abstract

Despite the recent development of vaccines and monoclonal antibodies preventing SARS-CoV-2 infection, treating critically ill COVID-19 patients still remains a top goal. In principle, drug repurposing – the use of an already existing drug for a new indication – could provide a shortcut to a treatment. However, drug repurposing is often very speculative due to the lack of clinical evidence. We here report on a methodology to find and test gene drug target candidates for drug repurposing. We matched critically ill COVID-19 cases from the UK Biobank with healthy controls and screened for significant differences in 33 blood cell types, 30 blood biochemistries, and body mass index in cases and controls. Significant differences in traits that have previously been associated with critically ill COVID-19 status, such as alanine aminotransferase, body mass index, C-reactive protein, and neutrophil cell count were further investigated. In-depth statistical analysis of COVID-19 associated traits and their genetics using regression modeling and propensity score stratification identified cyclin-dependent kinase 6 (CDK6) as a more promising drug target to selectively treat critically ill COVID-19 patients than the previously reported interleukin 6. Four existing CDK6 inhibitors abemaciclib, ribociclib, trilaciclib, and palbociclib have been approved for breast cancer. Clinical evidence for CDK6 inhibitors in treating critically ill COVID-19 has been reported. Further clinical investigations are ongoing.

Introduction

The phenotype of critically ill coronavirus disease 2019 (COVID-19) completely differs from mild or moderate disease, even among hospitalized cases, by an uncontrolled overreaction of the host's immune system[1–3] – a so-called virus-induced immunopathology[4] – resulting in acute respiratory distress syndrome (ARDS). Although the molecular mechanism leading to critically ill COVID-19 is still unclear, there is evidence that susceptibility and overreaction of the immune system to respiratory infections are both strongly heritable.[5,6] A series of genome-wide association (GWA) studies have been conducted to investigate disease pathogenesis in order to find mechanistic targets for therapeutic development or drug repurposing, as treating the disease remains a top goal despite the recent development of vaccines.[7–10]

The results of 46 GWA studies comprising 46,562 COVID-19 patients from 19 countries have been combined in three meta-analyses by the COVID-19 Host Genetics Initiative.[10] Overall, 15 independent genome-wide significant loci associations were reported forCOVID-19 infection in general, whereas six genome-wide significant associations were found to be associated with critical illness due to COVID-19. The six loci comprise 3p21.31 close to *CXCR6* that plays a role in chemokine signaling and *LZTFL1* that has been implicated in lung cancer; 12q24.13 in a gene cluster that encodes antiviral restriction enzyme activators; 17q21.31 with the *KANSL1* gene has been previously reported for reduced lung function; 19p13.3 within the gene that encodes dipeptidyl peptidase 9 (*DPP9*); 19p13.2 that encodes tyrosine kinase 2 (*TYK2*); 21q22.11 encoding for the interferon receptor gene *IFNAR2*. The functions of the identified genes are either related to host antiviral defense mechanisms or are mediators of inflammatory organ damage. These results are a

good starting point for a better understanding of host genetics in viral infections.

Nevertheless, none of the found genes encodes for an established drug target.

Consequently, these studies provide no evidence that supports drug repurposing.

We here present an approach for drug repurposing based on genetics of disease

associated traits instead of disease genetics. First, critically ill COVID-19 cases are

matched with healthy controls, and the two cohorts are investigated for significant

differences in previously reported traits. Traits that differ in cases and controls and that

have been associated with critically ill COVID-19 are further investigated to find and

test established drug target genes for drug repurposing.

Results

Screening for critically ill COVID-19 associated traits

Critically ill COVID-19 cases were selected from the UK Biobank[11] based on their

previously described phenotype definition. Critically ill COVID-19 cases are patients

who were hospitalized due to confirmed SARS-CoV-2 infection and who required

respiratory support and/or died due to infection.[12] We identified 8,153 cases in the UK

Biobank and selected age and sex matched healthy controls. In order to explore how

the critically ill cohort differed in general from healthy controls, we screened 64

candidate predictive traits (33 blood cell types, 30 blood biochemistries, and body

mass index) that had been measured years before the individuals were affected by

COVID-19 (Fig. 1). We observed statistically significant differences in 64 traits

confirmed by multiple statistical tests, independent two-sample t-test and Mann-

Whitney U-test[13], and Bonferroni correction ($p < \alpha/n = 0.05/64$)[14]. In these measures

taken years prior to infection, cases showed significant differences in various traits that

have been described as phenotypes for critically ill COVID-19. For instance, cases

had higher body mass index (BMI), higher reticulocyte cell count, higher inflammatory markers such as alanine aminotransferase, C-reactive protein, cystatin C, neutrophil cell count, and higher glycated hemoglobin (HbA1c), but lower HDL and LDL cholesterol as well as lower vitamin D level than healthy controls.

As an additional comparison group we selected infection disease cases from the UK Biobank to assess to what extent these traits are general indicators of predisposition to severe infections. In total 23,348 participants were selected who had been diagnosed with a respiratory infection, acute respiratory distress syndrome, influenza or pneumonia and were hospitalized or had died as a result. Again, cases were matched with healthy controls in order to screen 33 blood cell types, 30 blood biochemistries, and body mass index for statistically significant differences in these two cohorts. As in the COVID-19 investigation, we here found that cases had higher body mass index (BMI), higher reticulocyte cell count, higher inflammatory markers such as alanine aminotransferase, C-reactive protein, cystatin C, neutrophil cell count, and higher glycated hemoglobin (HbA1c), but lower HDL and LDL cholesterol as well as lower vitamin D levels than healthy controls (Supplementary Information Fig. 1 and Fig. 2).

Traits that have been previously associated with critically ill COVID-19 and infection diseases such as alanine aminotransferase, BMI, C-reactive protein, and neutrophil cell count were further investigated.[15,16]

GWAS results

We next focused on trait genetics of reported critically ill COVID-19 associated phenotypes such as BMI, neutrophil cell count, C-reactive protein, and alanine aminotransferase. We ran GWA analyses for these four traits and compared our

results with previously reported statistics available from the NHGRI-EBI GWAS

Catalog[17]. The identified genes were further investigated for already approved drug

molecules. We found *IL-6*, encoding for interleukin 6, reported for C-reactive protein[18]

and *CDK6,* encoding for cyclin-dependent kinase 6 (CDK6), reported for BMI[19] and

neutrophil cell count[20]. Unfortunately, we could not confirm the *IL-6* signal (rs2097677)

in our GWA analysis for C-reactive protein (Supplementary Information Fig. 3). We

continued our research with the reported drug target for interleukin 6 and interleukin 6

receptor (IL-6R). We furthermore confirmed single nucleotide polymorphisms (SNPs)

rs42044 and rs445 in the *CDK6* gene as significant in our GWA analyses for BMI and

neutrophil cell count (Supplementary Information Fig. 4). The allele distributions of

rs2097677, rs42044, and rs445 in cases and controls can be found in the

Supplementary Information Tab. 1 and 2.

Regression modeling

Logistic regression models were built to examine the relationship between a series of

candidate predictive traits (age, alanine aminotransferase, BMI, C-reactive protein,

and neutrophil cell count) and critically ill COVID-19 status. All of these traits apart

from age were significant predictors of critically ill COVID-19 (as illustrated for

neutrophil cell count in Fig. 2). As expected, no relationship between age and disease

status could be found as the members of the control group were matched with the

reported cases by age and sex. A drop one analysis revealed that all traits explain

unique variance in critically ill COVID-19 status.

Propensity score analysis

Propensity score analysis is a technique for estimating the effect of a treatment on an outcome independent of any observed factors that covary with that treatment and would otherwise make it impossible to determine causation. We specifically employed propensity score stratification using the propensity function of Imai and van Dyk[21] in order to determine whether a causal relationship exists between both C-reactive protein and neutrophil cell count and the prevalence of critically ill COVID-19 independently from other covariates. A weighted average across propensity deciles indicated a significant effect of C-reactive protein (Log Odds Ratio = 0.04; SE = 0.004; p = 1.3288e-26) and neutrophil cell count (Log Odds Ratio = 0.3; SE = 0.018; p = 2.7354e-61) on disease status. Tab. 2 shows the neutrophil cell count in the critically ill COVID-19 patients and the control group across the propensity deciles.

Mendelian randomization

Mendelian randomization (MR) is a robust and accessible tool to examine the causal relationship between an exposure variable and an outcome from GWAS summary statistics.[22] We employed two-sample summary data Mendelian randomization to further validate causal effects of neutrophil cell count genes on the outcome of critically ill COVID-19. We used independent GWAS summary data for neutrophil cell count (exposure) published by Vuckovic *et al.*[23] and summary data for critically ill COVID-19 (outcome) published by the COVID-19 Host Genetics Initiative[10]. As shown in the Supplementary Information Tab. 3, instrumental variable weight (IVW) was significant with a p value of 0.01199 when we used a lenient clumping parameter of r = 0.2 and 1,581 SNPs whereas we observed no significant IVW when we used strict clumping parameters of r = 0.01 and 567 SNPs (Supplementary Information Tab. 3).

Discussion

We have described a method for identifying drug targets for the treatment of disease

based not directly on the genetics of the disease itself but rather on the genetics of

disease-associated traits. Using data from the UK Biobank, we found evidence of a

causal relationship between a series of traits and critical illness due to COVID-19.

Using genome-wide associations we identified genetic markers associated with these

traits. Based on these two steps we were able to identify CDK6 as a potential drug

target for critically ill COVID-19. The four CDK6 inhibitors abemaciclib, palbociclib,

ribociclib, and trilaciclib have been already approved for breast cancer and can

potentially be repurposed to treat critically ill COVID-19.

Our procedure worked as follows. We matched reported critically ill COVID-19 cases

from the UK Biobank with healthy controls and checked for significant differences

between cases and controls in 64 candidate predictive traits. Cases showed significant

differences in alanine aminotransferase, BMI, C-reactive protein, and neutrophil cell

count. These measures were taken from the individuals concerned years before

infection. We hypothesize that the genetic drivers of a disease associated trait displays

a good drug target to treat the disease. In the literature we found the genes *IL-6*,

encoding interleukin 6, as a driver of C-reactive protein, and *CDK6*, encoding cyclin-

dependent kinase 6, as a driver of BMI and neutrophil cell count. Three drugs have

been already approved that inhibit interleukin 6 either directly (siltuximab for

Castleman's Disease) or indirectly via the interleukin 6 receptor (tocilizumab and

sarilumab for rheumatoid arthritis). The four drugs abemaciclib, palbociclib, ribociclib,

and trilaciclib are already approved for treatment of breast cancer target CDK4/6.

Regression models that tested all traits together showed that C-reactive protein and

neutrophil cell count explained independent variance in critically ill COVID-19 status

in the presence of other traits such as BMI. Propensity score stratification found

evidence of a causal relationship between both C-reactive protein and neutrophil cell

count and the prevalence of critically ill COVID-19 status.

It is important to note that Mendelian randomization results did not confirm a causal

role for either C-reactive protein or neutrophil cell count. However, MR is typically used

where there is a direct relationship between gene and outcome. In our case we are

looking for a relationship that is mediated by a viral infection, adding a great deal more

noise. This, compounded by the fact that MR needs a larger sample size[24] than we

have available, might account for our not finding evidence of a relationship in this

analysis.

The role of C-reactive protein in COVID-19 can be explained by the previously-

reported disease mechanism. The phenotype of critically ill COVID-19 completely

differs from mild or moderate disease, even among hospitalized cases, by an

uncontrolled overreaction of the host's immune system.[1–3] The most prominent

difference between critically ill and moderate COVID-19 cases is the response to

immunosuppressive therapy. In patients without respiratory failure, there is a trend

indicating that treatment with corticosteroid dexamethasone is harmful, whereas

among patients with critical respiratory failure, it has substantial benefit.[25] Therefore,

immunomodulatory therapies, such as interleukin 6 receptor (IL-6R) antagonists

tocilizumab and sarilumab have been successfully tested to block the immune

system's overreaction in form of a cytokine storm in critically ill COVID-19 patients.[26]

The role of neutrophil count in the disease mechanism can also be explained.

Neutrophils are white blood cells and an important component of our host defense

against invading pathogens. Critically ill COVID-19 status is characterized by

infiltration of the lungs with macrophages and neutrophils that cause diffuse lung

alveolar damage, the histological equivalent to ARDS.[27–29] Neutrophils develop a

sophisticated network of DNA called neutrophil extracellular traps (NETs) through

NETosis, a liberation of web-like structures of nucleic acids wrapped with histones that

detain viral particles.[30] However, ineffective clearance and regulation of NETs result

in pathological effects such as thromboinflammation as described above.[31] On the one

hand, NETs are essential and efficient for trapping the virus. And on the other, they

cause damage to the organism by triggering highly intense immunological and

inflammatory processes. CDK4/6 have been previously described as regulators of

NETosis. CDK4/6 inhibitors abemaciclib and palbociclib block NET formation in a

dose-responsive manner but do not inhibit the oxidative burst, phagocytosis, or

degranulation, indicating that CDK4/6 inhibition specifically affects NET production,

rather than generally modulating inflammatory pathways as IL-6 inhibitors do.[32]

There is good reason to think that IL-6 and CDK4/6 might both be good drug targets

for the treatment of COVID-19. However, given that neutrophils have a direct role in

the thromboinflammatory process in critically ill COVID-19 patients, we believe that

blocking neutrophils represents a more selective strategy than suppressing the

immune system as a whole. There are two phases of COVID-19 infection (Fig. 3). In

the beginning of infection, the virus enters the cell and starts viral replication. Here,

vaccines and monoclonal antibodies block the viral entry. Nonetheless, after entry into

the cell via the ACE2 receptor, currently, no therapeutic option for intervention exists.

After viral infection first immune reactions are observed such as a decrease of

lymphocyte cell count (lymphopenia). This phase is called the viral response phase.

In the beginning of the next phase, so-called host response phase, an overreaction of

the host immune system occurs. The detailed mechanism is still unknown why some

patients' host immune systems overreact. From our results here we assume that

already manifested inflammations observed by high C-reactive protein levels and high

neutrophil cell count trigger the immune system's overreaction resulting in thrombotic

inflammation in the lungs and, from there, respiratory failure. In summary, the host

response decides whether an infection disease like COVID-19 has a mild course or

leads to respiratory failure.

A central role in host response displays the cytokine IL-6. On one hand, IL-6 binds to

liver cells inducing the release of C-reactive protein that binds to phosphocholine of

dead cells and recruits phagocytes. On the other hand, IL-6 stimulates the production

of neutrophils and, thus, indirectly induces NETosis. Therefore, it is reasonable to

inhibit IL-6 in a therapeutic intervention. However, immunomodulators can only be

administered to tackle the overreaction of the immune system. Immunomodulators

given in the early infection phase are harmful for patients. In contrast to IL-6 inhibitors,

CDK4/6 inhibitors selectively block the NET formation and have no impact on other

important host immune reactions such as phagocytosis so that they can be given

earlier in the infection than IL-6 inhibitors filling the therapeutic gap between vaccines

and monoclonal antibodies in early infection and immunomodulators in the late stage.

Our statistical analyses identified an independent effect of neutrophil cell count on

critically ill COVID-19 status providing evidence that therapeutic intervention at this

later stage is still effective. We therefore hypothesize that CDK4/6 inhibitors are

superior to IL-6 inhibitors in the treatment of critically ill COVID-19 supported by the

reported cases of breast cancer patients and their disease course during a CDK4/6

therapy.

In view of the evidence we have presented here it is interesting to note the report of

Grinshpun *et al.*[33] that a breast cancer patient on a CDK4/6 inhibitor therapy had a

unique disease course, halting the full presentation of the disease. Once the drug was

withdrawn, the full classic spectrum of illness appeared, including a bothering

desaturation necessitating prolongations of hospital stay for close monitoring of the

need for invasive ventilations.[33]

To conclude – we propose CDK6 as a new and plausible drug target and the

repurposing of already-approved breast cancer drugs abemaciclib, ribociclib,

trilaciclib, and palbociclib as a possibly treatment against critically ill COVID-19.

CDK4/6 inhibitors have the advantage of targeting the thrombo inflammation earlier

and more selectively than reported IL-6 inhibitors. Additionally, CDK4/6 inhibitors are

chemical compounds and, from there, easier to store and administer than monoclonal

antibodies. Clinical evidence for CDK6 inhibitors in treating critically ill COVID-19 have

been already reported. Further clinical investigations are ongoing. We have also

presented a novel methodology to find and test gene drug target candidates for drug

repurposing in population data. Our approach is not limited to drug repurposing, but

can also be used to validate new drug targets. This highlights the importance of

Biobanks for global health in a pandemic.

Methods

Recruitment of cases and controls

The COVID-19 phenotype was defined based on the rich information made available

by the UK Biobank project, which has been collecting COVID-19 outcomes for their

large cohort of patients. The COVID-19 outcomes up until 28th October 2020 were

collected and cases were defined as reported previously.[8] Briefly, severe cases were

defined as patients who died or were hospitalized (cause of death or diagnosis

contains an ICD10 code for COVID-19 U071) or were on a ventilator (operation code

contains an E85*). Cases were not filtered based on COVID-19 test outcomes. The

remaining individuals from the UK Biobank were defined as potential controls.

Subsequently, patients of European ancestry were selected, and cases and controls

were matched for similar age and sex distributions, resulting in a matched number of

cases and controls (total number of subjects 16,307 with 8,153 cases and 8,154

controls). The dataset was used to perform a number of analyses described below.

The infection disease phenotype was created based on UK Biobank data for

respiratory infections, acute respiratory distress syndrome, influenza, and pneumonia

with hospitalization or death as a result. We aggregated hospital in-patient and death

register data from over 337,000 individuals in UK Biobank for ICD codes

corresponding to J00-J06, J09-J18, J80, and J20-J22 (UK Biobank Fields 41202,

41204, 40001, 40002, 41201, and 41270 for diseases and 40001 and 40002 for

deaths). The remaining individuals from the UK Biobank were defined as potential

controls. European ancestry was carried over and selected based on UK Biobank

phenotype as well as covariates information (age and sex) for the resulting dataset.

Covariate distributions were matched to result in the same number of cases and

controls. Variants reported by Pairo-Castineira et al.[8] and Ellinghaus et al.[7] as well as

variants reported by the ClinVar database[35] for the genes reported by the papers were

included in the dataset.

GWAS

The UK Biobank genotypes for the cases and controls were extracted to create a

dataset that was then submitted to a series of quality control steps with an aim to

remove biases in the downstream analysis as described in Marees *et al.*[34] First we

filtered SNPs and individuals based on their missingness in the dataset. This excludes

SNPs that have a high proportion of subjects where genotyping information is

unavailable or of poor quality. Similarly, individuals where a large proportion of SNPs

could not be measured were excluded. This was achieved in two steps, where first a

lenient threshold of 0.2 (i.e. > 20%) was applied to remove the clear outliers, followed

by a more stringent threshold of 0.02 (i.e. > 2%). SNP filtering was performed before

individual filtering. Next, all variants not on autosomal chromosomes were removed.

Next, variants that deviate from the Hardy-Weinberg equilibrium were removed in a

two-step process whereby we first applied a lenient threshold of 1e-6, followed by a

more stringent threshold of 1e-10. This is a common indicator of genotyping errors.

Thereafter, individuals were filtered out based on their heterozygosity rates which can

indicate sample contamination. Individuals deviating by more than 3 standard

deviations from the mean of the rate from all samples were filtered out. To assess the

heterozygosity rate per sample, those variants that were in linkage disequilibrium with

each other were extracted by scanning the genome at a window size of 50 variants, a

step size of 5, and a pairwise correlation threshold of 0.2. Next, related individuals

were removed. To achieve this, their identity by descent coefficients (IBD) were

calculated and only one individual per related cluster was kept. Then, the small

proportion of missing genotypes were imputed and additional variants reported by

Pairo-Castineira *et al.*[8] and Ellinghaus *et al.*[7] as well as variants reported by ClinVar

database[35] were included in the dataset from the UK Biobank imputed variants. This

yielded a dataset with a total number of 335,332 quality controlled variants. Finally,

the population structure of the samples was analyzed in two stages to identify internal

stratifications, which was used to filter out any individuals not predicted close enough

to a European reference cohort. A genome-wide association analysis was performed

with the R-package SAIGE[36] to score individual variants for their association with

critically ill COVID-19.

Regression modeling

Logistic regression models were fitted using the *glm* function in R (www.R-project.org).

A drop one model comparison procedure was performed in order to determine whether

each of a set of traits account for unique variance in critically ill COVID-19 disease

status.

Propensity score analysis

Using the method of Imai and Van Dyk[21], we regressed neutrophil count on BMI, age,

and gender and then used the resulting model predictively in order to generate

propensity values for our population. We then stratified the population into propensity

deciles (the members of which are approximately matched in terms of their

propensity), estimated the effects of z-transformed neutrophil count on disease status

within each band using logistic regression, and calculated a weighted average.

Mendelian randomization

We used independent GWAS summary data for neutrophil cell count (exposure)

published by Vuckovic *et al.*[23] (GCST90002398 downloaded January 15th 2021) and

summary data for critically ill COVID-19 (outcome) published by the COVID-19 Host

Genetics Initiative (https://www.covid19hg.org/results - COVID19hg GWAS meta-

analyses round 5 release date January 18th 2021). Two-sample MR analyses were

done as previously described.[10]

Acknowledgment

The research has been conducted using the UK Biobank Resource under Application no. 36226. We thank Radi Hilaneh for making Fig. 3. The research work was supported by the *Investitionsbank des Landes Brandenburg* (ILB), the European Regional Development Fund (ERDF), and the European Social Fund+ (ESF+). Access to the UK Biobank was funded by the EIT Health Digital Sandbox program to access European biobank data (grant number 2019-DS1001-3754). We also thank the program 'digital solutions made in Brandenburg' (digisolBB) for its continued support.

Competing interests

J.E.K., C.N.J.R., M.R.J.L., H.A.B., J.L.C., and M.F.S are employees of biotx.ai GmbH. A.R.E.S was an employee of biotx.ai GmbH.

References

1. Berlin, D. A., Gulick, R. M. & Martinez, F. J. Severe Covid-19. *N. Engl. J. Med.* **383**, 2451–2460 (2020).

2. Fajgenbaum, D. C. & June, C. H. Cytokine Storm. *N. Engl. J. Med.* **383**, 2255–2273 (2020).

3. Millar, J. E. *et al.* Robust, reproducible clinical patterns in hospitalised patients with COVID-19. *medRxiv* (2020).

4. Rouse, B. T. & Sehrawat, S. Immunity and immunopathology to viruses: what decides the outcome? *Nat. Rev. Immunol.* **10**, 514–526 (2010).

5. Casanova, J.-L. Severe infectious diseases of childhood as monogenic inborn
errors of immunity. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E7128–37 (2015).

6. Horby, P., Nguyen, N. Y., Dunstan, S. J. & Baillie, J. K. An updated systematic
review of the role of host genetics in susceptibility to influenza. *Influenza Other*
Respi. Viruses **7 Suppl 2**, 37–41 (2013).

7. Severe Covid-19 GWAS Group *et al.* Genomewide Association Study of Severe
Covid-19 with Respiratory Failure. *N. Engl. J. Med.* **383**, 1522–1534 (2020).

8. Pairo-Castineira, E. *et al.* Genetic mechanisms of critical illness in COVID-19.
Nature **591**, 92–98 (2021).

9. Zhang, Q. *et al.* Inborn errors of type I IFN immunity in patients with life-
threatening COVID-19. *Science* **370**, (2020).

10. The COVID-19 Host Genetics Initiative & Ganna, A. Mapping the human genetic
architecture of COVID-19 by worldwide meta-analysis. *medRxiv*
2021.03.10.21252820 (2021).

11. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic
data. *Nature* **562**, 203–209 (2018).

12. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial
Version 7). *Chin. Med. J.* **133**, 1087–1095 (2020).

13. Fay, M. P. & Proschan, M. A. Wilcoxon-Mann-Whitney or t-test? On assumptions
for hypothesis tests and multiple interpretations of decision rules. *Stat. Surv.* **4**,
1–39 (2010).

14. Dunn, O. J. Multiple Comparisons among Means. *J. Am. Stat. Assoc.* **56**, 52–64
(1961).

15. Osuchowski, M. F. *et al.* The COVID-19 puzzle: deciphering pathophysiology and

phenotypes of a new disease entity. *Lancet Respir Med* (2021)

doi:10.1016/S2213-2600(21)00218-6.

16. Zhang, B. *et al.* Clinical characteristics of 82 cases of death from COVID-19.

PLOS ONE vol. 15 e0235458 (2020).

17. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide

association studies, targeted arrays and summary statistics 2019. *Nucleic Acids*

Res. **47**, D1005–D1012 (2019).

18. Okada, Y. *et al.* Genome-wide association study for C-reactive protein levels

identified pleiotropic associations in the IL6 locus. *Hum. Mol. Genet.* **20**, 1224–

1231 (2011).

19. Hübel, C. *et al.* Genomics of body fat percentage may contribute to sex bias in

anorexia nervosa. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **180**, 428–438

(2019).

20. Lin, B. D. *et al.* 2SNP heritability and effects of genetic variants for neutrophil-to-

lymphocyte and platelet-to-lymphocyte ratio. *J. Hum. Genet.* **62**, 979–988 (2017).

21. Imai, K. & van Dyk, D. A. Causal inference with general treatment regimes. *J.*

Am. Stat. Assoc. **99**, 854–866 (2004).

22. Katan, M. B. Apolipoprotein E isoforms, serum cholesterol, and cancer. *Lancet*

1, 507–508 (1986).

23. Vuckovic, D. *et al.* The Polygenic and Monogenic Basis of Blood Traits and

Diseases. *Cell* **182**, 1214–1231.e11 (2020).

24. Burgess, S. Sample size and power calculations in Mendelian randomization with

a single instrumental variable and a binary outcome. *Int. J. Epidemiol.* **43**, 922–

929 (2014).

25.   RECOVERY Collaborative Group *et al.* Dexamethasone in Hospitalized Patients

442   with Covid-19. *N. Engl. J. Med.* **384**, 693–704 (2021).

443   26.   REMAP-CAP Investigators *et al.* Interleukin-6 Receptor Antagonists in Critically

444   Ill Patients with Covid-19. *N. Engl. J. Med.* (2021) doi:10.1056/NEJMoa2100433.

445   27.   Schaller, T. *et al.* Postmortem Examination of Patients With COVID-19. *JAMA*

446   **323**, 2518–2520 (2020).

447   28.   Nicholls, J. M. *et al.* Lung pathology of fatal severe acute respiratory syndrome.

448   *Lancet* **361**, 1773–1778 (2003).

449   29.   Tian, S. *et al.* Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus

450   (COVID-19) Pneumonia in Two Patients With Lung Cancer. *J. Thorac. Oncol.* **15**,

451   700–704 (2020).

452   30.   Brinkmann, V. *et al.* Neutrophil extracellular traps kill bacteria. *Science* **303**,

453   1532–1535 (2004).

454   31.   Cheng, O. Z. & Palaniyar, N. NET balancing: a problem in inflammatory lung

455   diseases. *Front. Immunol.* **4**, 1 (2013).

456   32.   Amulic, B. *et al.* Cell-Cycle Proteins Control Production of Neutrophil

457   Extracellular Traps. *Dev. Cell* **43**, 449–462.e5 (2017).

458   33.   Grinshpun, A., Merlet, I., Fruchtman, H. & Nachman, D. A Protracted Course of

459   COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor

460   Therapy. *Front. Oncol.* **10**, 1085 (2020).

461   34.   Marees, A. T. *et al.* A tutorial on conducting genome-wide association studies:

462   Quality control and statistical analysis. *Int. J. Methods Psychiatr. Res.* **27**, e1608

463   (2018).

464   35.   Landrum, M. J. *et al.* ClinVar: improvements to accessing data. *Nucleic Acids*

465   *Res.* **48**, D835–D844 (2020).

466 36. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample

467 relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–

468 1341 (2018).

Figures & Tables

Figure 1

Fig. 1. Statistically significant differences in 36 traits confirmed by Mann-Whitney U-test and Bonferroni correction. In these measures taken years prior to infection, cases showed significant differences in the characteristics in various traits that have been later described as phenotypes for critically ill COVID-19. For instance, cases had higher body mass index (BMI), higher reticulocyte cell count, higher inflammatory markers such as alanine aminotransferase, C-reactive protein, cystatin C, neutrophil cell count, and higher glycated hemoglobin (HbA1c), but lower HDL and LDL cholesterol as well as lower vitamin D level than healthy controls.

483   **Figure 2**

485   **Fig. 2.** Regression model uncovered that neutrophil cell count measured years prior

486   to infection correlates with the prevalence of critically ill COVID-19.

Figure 3

Fig. 3. COVID-19 infection stages. In the beginning of the infection the virus enters

the cell and starts viral replication. Here, vaccines and monoclonal antibodies block

the viral entry. After entry into the cell via the ACE2 receptor, currently, no therapeutic

option for intervention exists. First immune reactions are observed such as a decrease

of lymphocyte cell count (lymphopenia). This phase is called the viral response phase.

In the beginning of the next phase, so-called host response phase, an overreaction of

the host immune system occurs. The detailed mechanism is still unknown why some

patients' host immune systems overreact. A central role in host response displays the

cytokine IL-6. On one hand, IL-6 binds to liver cells inducing the release of C-reactive

protein that binds to phosphocholine of dead cells and recruits phagocytes. On the

other hand, IL-6 stimulates the production of neutrophils and, thus, indirectly induces

NETosis. Therefore, it is reasonable to inhibit IL-6 in a therapeutic intervention.

However, immunomodulators can only be administered to tackle the overreaction of

the immune system. Immunomodulators given in the early infection phase are harmful

for patients. In contrast to IL-6 inhibitors, CDK4/6 inhibitors selectively block the NET

formation and have no impact on other important host immune reactions such as

phagocytosis so that they can be given earlier in the infection than IL-6 inhibitors filling

the therapeutic gap between vaccines and monoclonal antibodies in early infection

and immunomodulators in the late stage.

Table 1

Tab. 1. Critically ill COVID-19 status was regressed on age, alanine aminotransferase, BMI, C-reactive protein, and neutrophil cell count. All traits other than age were found to explain unique variance in disease status. This table reports log likelihood ratios, standard errors and likelihood ratio tests from the drop one procedure for each.

	Estimate	Std. Error	χ^2	*p* value
(Intercept)	-2.550189	0.106980		
Alanine aminotransferase	0.004023	0.001190	11.94	0.00055
BMI	0.055657	0.003507	264.15	< 2.2e-16
C-reactive protein	0.026724	0.003629	59.61	1.155e-14
Neutrophil cell count	0.167327	0.011667	215.99	< 2.2e-16

Table 2

Tab. 2. Propensity score matching was employed in order to determine whether a causal relationship exists between neutrophil cell count and the prevalence of critically ill COVID-19. A weighted average across propensity deciles indicates a significant effect of neutrophil cell count (Log Odds Ratio = 0.3; SE = 0.018; p = 2.7354e-61) on disease status. The table shows the neutrophil cell count in the critically ill COVID-19 and control groups across the propensity deciles.

Propensity score decile	1	2	3	4	5	6	7	8	9	10
Controls neutrophil cell count in 10^9 cells/liter	4.08	3.98	4.1	4.17	4.3	4.39	4.39	4.49	4.58	4.8
Cases neutrophil cell count in 10^9 cells/liter	4.61	4.68	4.55	4.6	4.77	4.84	4.85	4.85	4.9	5.2

Supplementary information

SI Fig. 1. Distribution of neutrophil cell count in critically ill COVID-19 cases (orange) and healthy controls (blue).

SI Fig. 2. As an additional comparison group we selected infection disease cases from the UK Biobank. In total 23,348 participants had been diagnosed with a respiratory infection, acute respiratory distress syndrome, influenza, or pneumonia and were hospitalized or died as a result. Again, the cases were matched with healthy controls in order to screen 64 candidate predictive traits for statistically significant differences in these two groups. Analogously to the COVID-19 investigations we here also found that cases had higher body mass index (BMI), higher reticulocyte cell count, higher inflammatory markers such as alanine aminotransferase, C-reactive protein, cystatin C, neutrophil cell count, and higher glycated hemoglobin (HbA1c), but lower HDL and LDL cholesterol as well as lower vitamin D level than healthy controls.

579 **SI Fig. 3.** Manhattan plot of C-reactive protein indicating that we did not reproduce the

580 reported *IL-6* signal (rs2097677) on chromosome 7.

590 **SI Fig. 4.** Manhattan plot of neutrophil cell count showing that we reproduce the

591 reported *CDK6* signal (rs445) on chromosome 7.

606 **SI Tab. 1.** Distribution of allele carriers rs2097677 (*IL-6*), rs445 (*CDK6*), and rs 42044

607 (*CDK6*) in cases and controls.

	Cases	Controls
rs2097677 AA	492	504
rs2097677 AG	2944	2981
rs2097677 GG	4418	4445
rs445 CC	81	74
rs445 CT	1365	1419
rs445 TT	6417	6446
rs42044 GG	581	632
rs42044 GT	3140	3102
rs42044 TT	4133	4191

621 **SI Tab. 2.** Distribution of allele combination carriers rs445 (*CDK6*), and rs 42044

622 (*CDK6*) in cases and controls.

	rs42044 GG	rs42044 GT	rs42044 TT
rs445 CC	352 cases / 372 ctrls	2348 cases / 2295 ctrls	3709 case / 3768 ctrls
rs445 TC	199 cases / 230 ctrls	754 cases / 778 ctrls	411 cases / 408 ctrls
rs445 TT	30 cases / 30 ctrls	38 cases / 29 ctrls	13 cases / 15 ctrls

642 **SI Tab. 3.** The two sample MR analyses here showed that for neutrophil cell count as

643 exposure and critically ill COVID-19 as outcome while using strict clumping

644 parameters, no significant effect was detected. This approach is limited by the quality

645 and sample size of critically ill COVID-19 GWASs.

	Clumping parameters	SNPs used	beta	SE	IVW p-value	Pleiotropy test
Exposure: neutrophil cell count Outcome: critically ill COVID-19	Lenient (r = 0.2)	1,581	-0.11139	0.04433	0.01199	negative
	Strict (r = 0.01)	567	0.01135	0.06987	0.87095	negative